The growing eye industry is something investors can’t ignore much longer.
Of your five senses, eyesight ranks right at the top. And when eyes are affected by various conditions, people will do what they can to alleviate their symptoms and improve their eye condition.
Dry eye disease is one of the most common ocular eye conditions. It’s no surprise that the market has become extensive for dry eye drugs including brand names like Novartis’ Xiidra and Allergan’s Restasis.
These drugs are expensive too. Xiidra is not usually covered by Medicare insurance plans and there is no generic alternative available for Xiidra. Restasis is a prescription eye drop that increases tear production to relieve chronic dry eye and can also cost hundreds of dollars.
Not to mention that both drugs come with side effects, have inadequate efficacy, and a slow onset of action.
Healthcare research for the eyes is laying the groundwork for drug technology that has never been seen before and treatments and therapies are becoming more sophisticated with every passing year.
Click to continue reading…